Research
Hormonal
Gastrointestinal tract adverse events were reported by 63.4% of participants on semaglutide.
Practitioners should monitor for gastrointestinal side effects in patients taking semaglutide.
StrongSupportsmedium confidence
Gastrointestinal tract adverse events were reported by 85 of 134 participants (63.4%) with semaglutide.
Why this rating
Based on a randomized clinical trial design.
Source
Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes
Takashi Kadowaki et al. · JAMA Internal Medicine · 2025
DOI 10.1001/jamainternmed.2025.3599
rct · n=201Cited 9×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →